Lund, Sweden, 15:00 CET, 19 October 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces that the company, through a 510 (k) to the Food and Drug Administration (FDA), has updated its CERAMENT® BONE VOID FILLER (BVF) instructions for use for the US market. The update includes clarification of the indication bone cysts and tumors to include adults and children above the age of nine.
For more information contact:
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The Company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT®|G is planned in 2021. The Company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.